Oxford–Cambridge Arc

Turn Europe's strongest research corridor into a commercialisation corridor, so that more discoveries become British companies with British-owned intellectual property.

• More discoveries commercialised in Britain rather than licensed abroad
• Intellectual property retained and financed domestically
• Growth-stage companies staying through scale rather than selling early

Comparable in function to Biopolis and Fusionopolis, or Technion and the Israel Innovation Park.

• Europe's strongest concentration of research capability.
• High density of world-leading laboratories and university spin-outs.
• Established science parks and an experienced deep-tech investor base.
• Existing pharmaceutical and biotech presence including AstraZeneca, GSK and Moderna UK.

• Cambridge Biomedical Campus
• Oxford Science Park
• Wellcome Sanger Institute
• Quantum computing laboratories
• Linkages to the Crick Institute in London

• Spin-out founders and technology transfer teams
• Pharmaceutical and medical device companies
• Deep-tech and life-science investors
• Clinical and regulatory expertise

• Life sciences and biotech
• Genomics
• Quantum computing
• Advanced materials
• MedTech
• University spin-outs

• University of Oxford
• University of Cambridge
• Wellcome Sanger Institute

• Wet and dry laboratory space
• Scale-up manufacturing for biologics and devices
• High-performance computing
• Housing and transport connectivity across the corridor

1. Research→
2. Problem→
3. Prototype→
4. Company→
5. Capital→
6. Customer→
7. Scale→
8. Export

• More discoveries commercialised in Britain rather than licensed abroad
• Intellectual property retained and financed domestically
• Growth-stage companies staying through scale rather than selling early

Described as outcomes rather than forecasts. UKIZ makes no projections it cannot evidence.